Swedish Orphan Biovitrum
318.8
SEK
-1.24 %
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
5 following
-1.24%
+0.44%
+4.39%
+4.32%
+16.95%
+18.25%
+80.31%
+112.11%
+568.08%
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Read moreMarket cap
113.49B SEK
Turnover
33.03M SEK
Revenue
22.12B
EBIT %
18.38 %
P/E
42.68
Dividend yield-%
-
Financial calendar
5/2
2025
Annual report '24
29/4
2025
Interim report Q1'25
8/5
2025
General meeting '24
ShowingAll content types
Swedish Orphan Biovitrum AB: Kommuniké från Sobis extra bolagsstämma
Swedish Orphan Biovitrum AB: Sobi visar sin styrka inom hematologi på ASH 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools